Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Nafarelin | hsa00071 | Fatty acid degradation | 3.77E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Nafarelin | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | Nafarelin | hsa00500 | Starch and sucrose metabolism | 2.10E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Nafarelin | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | Nafarelin | hsa00970 | Aminoacyl-tRNA biosynthesis | 9.32E-03 | 3 | O95363, P54136, Q15046 | FARS2, RARS1, KARS | More | | Nafarelin | hsa01100 | Metabolic pathways | 4.11E-02 | 7 | P30041, P20839, P08237, Q86XP1, Q9UHK6, Q86VZ5, Q9NVH6 | PRDX6, IMPDH1, PFKM, DGKH, AMACR, SGMS1, TMLHE | More | | Nafarelin | hsa01200 | Carbon metabolism | 4.06E-02 | 5 | P37837, O14521, P50213, P60891, Q02252 | TALDO1, SDHD, IDH3A, PRPS1, ALDH6A1 | More | | Nafarelin | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Nafarelin | hsa03013 | RNA transport | 4.73E-02 | 9 | P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, TACC3 | More | | Nafarelin | hsa04080 | Neuroactive ligand-receptor interaction | 8.48E-03 | 9 | P08311, P48058, Q15722, Q9H228, P43657, Q01726, P41968, P21730, P35318 | CTSG, GRIA4, LTB4R, EDG8, P2RY5, MC1R, MC3R, C5AR1, ADM | More | | Nafarelin | hsa04330 | Notch signaling pathway | 7.49E-03 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | Nafarelin | hsa04613 | Neutrophil extracellular trap formation | 9.53E-03 | 13 | P17252, O60603, P08246, Q9UM07, Q92769, Q6FI13, P14598, Q15080, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, ELA2, PADI4, HDAC2, H2AC18; H2AC19, NCF1, NCF4, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Nafarelin | hsa04640 | Hematopoietic cell lineage | 1.13E-02 | 8 | P13612, P14778, P27930, P15144, P07766, P09693, P01732, P01730 | ITGA4, IL1R1, IL1R2, ANPEP, CD3E, CD3G, CD8A, CD4 | More | | Nafarelin | hsa04650 | Natural killer cell mediated cytotoxicity | 2.05E-03 | 9 | P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Nafarelin | hsa04658 | Th1 and Th2 cell differentiation | 1.27E-04 | 9 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, P23771, Q9UL17 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, GATA3, TBX21 | More | | Nafarelin | hsa04659 | Th17 cell differentiation | 1.64E-04 | 10 | Q04759, Q16539, P01730, P06239, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Nafarelin | hsa04660 | T cell receptor signaling pathway | 6.29E-04 | 10 | Q04759, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | PRKCQ, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Nafarelin | hsa04912 | GnRH signaling pathway | 3.39E-02 | 4 | P17252, Q16539, Q9Y6R4, Q14643 | PRKCA, MAPK14, MAP3K4, ITPR1 | More | | Nafarelin | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | Nafarelin | hsa04919 | Thyroid hormone signaling pathway | 3.71E-02 | 2 | P26678, P08237 | PLN, PFKM | More | | Nafarelin | hsa04972 | Pancreatic secretion | 3.86E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Nafarelin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.76E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | Nafarelin | hsa05135 | Yersinia infection | 1.52E-02 | 6 | P13612, P06239, Q16539, P49841, P01730, P01732 | ITGA4, LCK, MAPK14, GSK3B, CD4, CD8A | More | | Nafarelin | hsa05146 | Amoebiasis | 2.10E-02 | 6 | P09341, P14778, P27930, P05089, P12814, P08311 | CXCL1, IL1R1, IL1R2, ARG1, ACTN1, CTSG | More | | Nafarelin | hsa05222 | Small cell lung cancer | 4.26E-02 | 6 | P10826, Q13489, P10415, Q13077, O00463, P24522 | RARB, BIRC3, BCL2, TRAF1, TRAF5, GADD45A | More | | Nafarelin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.79E-03 | 7 | P07766, P20963, P09693, P06239, Q04759, Q16539, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, MAPK14, CD4 | More | | Nafarelin | hsa05340 | Primary immunodeficiency | 3.76E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Nafarelin | hsa05415 | Diabetic cardiomyopathy | 3.19E-02 | 7 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P14780 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, MMP9 | More | | |